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ABSTRACT Secretory human phospholipase A2 type IIA (PLA2-IIA) catalyzes the hydrolysis of the sn-2 ester bond in
glycerolipids to produce fatty acids and lysolipids. The enzyme is coupled to the inﬂammatory response, and its speciﬁcity
toward anionic membrane interfaces suggests a role as a bactericidal agent. PLA2-IIA may also target perturbed native cell
membranes that expose anionic lipids to the extracellular face. However, anionic lipid contents in native cells appear lower than
the threshold levels necessary for activation. By using phosphatidylcholine/phosphatidylglycerol model systems, we show that
local enrichment of anionic lipids into ﬂuid domains triggers PLA2-IIA activity. In addition, the compositional range of enzyme
activity is shown to be related to the underlying lipid phase diagram. A comparison is done between PLA2-IIA and snake venom
PLA2, which in contrast to PLA2-IIA hydrolyzes both anionic and zwitterionic membranes. In general, this work shows that PLA2-
IIA activation can be accomplished through local enrichment of anionic lipids into domains, indicating a mechanism for PLA2-IIA
to target perturbed native membranes with low global anionic lipid contents. The results also show that the underlying lipid
phase diagram, which determines the lipid composition at a local level, can be used to predict PLA2-IIA activity.
INTRODUCTION
The phospholipase A2 (PLA2) subtypes comprise a diverse
family of enzymes that catalyze the hydrolysis of the sn-2
ester bond in glycerophospholipids, yielding free fatty acids
and lysophospholipids (1). The ﬁrst nonpancreatic mamma-
lian PLA2 to be reported (2,3) was a 14-kDa calcium-depen-
dent secretory PLA2 species, classiﬁed under the IIA group.
PLA2-IIA is closely related to the inﬂammatory process (4),
being involved in many acute and chronic inﬂammatory dis-
eases. Large quantities of the enzyme were found in the
synovial ﬂuids in inﬂammatory arthritis (5). The enzyme is
involved in the production of arachidonic acid (6), a precur-
sor of bioactive eicosanoids. The enzyme has been found to
be secreted by inﬂammatory effectors such as macrophages
and mast cells (7–9), and the expression of the enzyme is
regulated by proinﬂammatory cytokines (10). PLA2-IIA con-
centrations increase drastically in serum for a variety of in-
ﬂammatory disorders, and high local levels of the enzyme
are measured in inﬂamed tissues (9,11). PLA2-IIA has also
been found to be overexpressed in the environment sur-
rounding malignant tumors, and has been linked to increased
aggressiveness of the tumor (12,13).
One of the distinguishing characteristics of PLA2-IIA is its
speciﬁcity toward anionic membranes (14,15). The enzyme’s
activity toward neutral membranes composed of zwitterionic
lipids such as phosphocholines is practically nonexistent,
being several orders of magnitude lower than its activity
toward anionic membranes (16). The speciﬁcity of the en-
zyme toward anionic membranes is a result of the electro-
static nature of the binding interactions between the enzyme
and the surface (14,15,17). The enzyme has a relatively large
patch of cationic residues at the surface that provide non-
speciﬁc electrostatic interactions, which promote binding to
the anionic surface (15). Conversely, other PLA2 types, such
as those isolated from snake venom, lack the large number of
cationic residues found in PLA2-IIA (18). These species are
able to bind and hydrolyze both zwitterionic and anionic
lipid membranes, and do not exhibit the speciﬁcity of the
PLA2-IIA (19). The lack of activity of PLA2-IIA toward
zwitterionic membranes has been explained by the absence
of a key tryptophan found in the snake venom PLA2 species,
which is essential for the nonpolar interaction with the zwit-
terionic membrane (17). The speciﬁcity of PLA2-IIA has
important physiological consequences. The outer leaﬂet of
the plasma membrane of unperturbed mammalian cells are
characterized by a neutral lipid composition enriched in
sphingomyelin, phosphatidylcholines, and cholesterol (20).
Unperturbed cells are therefore poor substrates for extracel-
lular PLA2-IIA (14), and this is likely to prevent indiscriminate
hydrolysis of healthy cells during PLA2-IIA upregulation.
Although its function during the inﬂammatory process is
under discussion, the speciﬁcity of PLA2-IIA toward anionic
interfaces points to its role as an antibacterial agent (21).
PLA2-IIA is found to penetrate the highly anionic peptido-
glycan bacterial cell wall, and hydrolyze to a large extent the
phosphatidylglycerol lipids found at the bacterial membrane
surface (21). This antimicrobial role appears to explain the
high levels of PLA2-IIA found in tear ﬂuid (22–24), and
the close relationship between PLA2-IIA levels and the
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inﬂammatory response, which is normally triggered in the
vicinity of wound sites. However, other lines of evidence
also suggest that perturbed native cell membranes become
vulnerable to PLA2-IIA hydrolysis. Apoptotic cells, for ex-
ample, expose anionic lipids to the outer leaﬂet as a result of
loss in membrane asymmetry, resulting in an anionic mem-
brane surface prone to PLA2-IIA activity (25).
It has been pointed out that, after reaching equilibration
across the bilayer during loss in membrane asymmetry, anionic
lipid contents are not sufﬁciently high to induce binding of
PLA2-IIA to the membrane surface (14), and that other
factors must play a role in enhancing PLA2-IIA activity on
perturbed cell systems. Some of the factors that have been
suggested include an increase in phophatidic acid levels (14).
In this article, we investigate how membrane heterogene-
ity and domain formation can play a role in enhancing PLA2-
IIA activity. Previous work has shown that snake venom
PLA2 species are sensitive to membrane heterogeneity (26–
28). Several studies have demonstrated that snake venom
PLA2 exhibits increased activity in the presence of lipid
domains. In particular, in a one-component dipalmitoylphos-
phatidylcholine (DPPC) system the lag time for snake venom
PLA2, which is a latency period of low hydrolysis observed
before a sudden burst in activity, reaches a minimum in the
vicinity of the main phase-transition temperature (29,30). In
a more physiologically relevant study, erythrocyte mem-
branes were shown to become more vulnerable to hydrolysis
by snake venom PLA2 as a result of an increase in membrane
heterogeneity induced by an inﬂux of Ca21 (31–33). This
increase in activity of snake venom PLA2 in the presence of a
domain structure has been attributed to the formation of
structural defects at the domain interface, which provide
better access of the enzyme to its substrate (29).
Still unexplored are the questions of how lipid domains
may regulate the activity of PLA2-IIA, and what similarities
can be drawn from the snake venom PLA2 results. In par-
ticular, it is necessary to explore how the speciﬁcity of PLA2-
IIA toward anionic membrane surfaces couples with the
potential for lipid domains to regulate PLA2-IIA activity. In
this article, we investigate these aspects using simple binary
model systems and ﬁnd that domain formation can act as an
enhancer of PLA2-IIA activity in membranes with low an-
ionic lipid content. However, in contrast to the snake venom
PLA2 results, where enhanced PLA2 activity is a result of
structural defects in the gel-ﬂuid interface, the increased
activity of PLA2-IIA in the presence of domains is induced
by compositional heterogeneity and segregation of anionic
lipids in the membrane surface. More speciﬁcally, domain
formation induced by lipid phase separation results in
regions enriched in anionic lipids, which trigger PLA2-IIA
activity. The results described here therefore open the pos-
sibility that, in perturbed cell membranes presenting low
anionic lipid contents in the outer leaﬂet, activation of PLA2-
IIA can be induced through the formation of ﬂuid-phase lipid
domains enriched in anionic lipids.
MATERIALS AND METHODS
1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC), 1,2-distearoyl-
sn-glycero-3-phosphocholine (DSPC), 1,2-dimyristoyl-sn-glycero-3-[phos-
pho-rac-(1-glycerol)] (DMPG, a sodium salt), 1,2-distearoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)] (DSPG, a sodium salt), and 1,2-di-O-octadecyl-
sn-glycero-3-phosphocholine (1,2-di-O-SPC, nonhydrolizable ether lipid for
calcein encapsulation) were purchased from Avanti Polar Lipids (Alabaster,
AL) and were used without further puriﬁcation. Calcein (2,4-bis-(N,N9-
di(carboxymethyl)aminomethyl)-ﬂuorescein) was purchased from ICN Bio-
chemicals (Costa Mesa, CA). Sephadex G-50 was purchased from Pharmacia
(Uppsala, Sweden). The speciﬁc PLA2-IIA inhibitor LY311727 was kindly
provided by Eli Lilly (Indianapolis, IN). Tear ﬂuid was used as the source
for human PLA2-IIA. Tear ﬂuid was collected from ﬁve healthy volunteers
exposed to onion fumes and was pooled together. For the hydrolysis ex-
periments, 10 ml of tear ﬂuid was added for each aliquot. Tear ﬂuid has a
high concentration of PLA2-IIA and is the only prevalent PLA2 species
found in tears. The PLA2-IIA content in tears in healthy subjects (54.5 mg/
ml) is one of the highest amounts of PLA2-IIA content reported in human
secretions (22–24). Puriﬁed snake venom PLA2 was a generous gift from Dr.
R. L. Biltonen (University of Virginia, Charlottesville, VA). This PLA2
enzyme belongs to the class of low-molecular-weight 14-kDa secretory
enzymes that display the capability of hydrolyzing both anionic and
zwitterionic membranes (18).
Preparation of liposomes
Phosphoglycerol (PG) and phosphocholine (PC) liposomes
Appropriate amounts of lipid were dissolved and mixed in CHCl3/MeOH
9:1, placed under a stream of nitrogen gas, and dried under vacuum
overnight. The dried lipids were dispersed in HEPES hydrolysis buffer (150
mM KCl, 10 mM HEPES, 30 mM CaCl2, 10 mM EDTA, pH 7.5) to a ﬁnal
concentration of 10 mM. Aqueous multilamellar lipid dispersions were
prepared by repeated heating to 65C, followed by vortexing for 15 min. The
multilamellar vesicles were extruded using a Lipex Biomembranes (Vancou-
ver, Canada) extruder 10 times through two stacked 100-nm-pore size poly-
carbonate ﬁlters (Whatman, Clifton, NJ), forming large unilamellar vesicles
with a narrow size distribution. The extruder temperature was regulated using
a water bath and was set to 65C for all samples.
Calcein-enclosed 1,2-di-O-SPC liposomes
An appropriate amount of calcein (50 mM ﬁnal concentration before adding
to lipids) was dissolved in 5 ml of 1 M NaOH. After the calcein was fully
dissolved, 2.5 ml of HEPESKCl-adjusted buffer (1MKCl, 100mMHEPES,
300 mM CaCl2, 100 mM EDTA, pH 7.5) was added together with 5 ml of
MilliQ water (Millipore, Bedford, MA). The solution was then pH-adjusted
to 7.5 with 1 M HCl dropwise to avoid precipitation. MilliQ water was then
added to bring the calcein buffer to a ﬁnal volume of 25 ml. 1,2-di-O-SPC
unilamellar vesicles were prepared in the same manner as the phosphogly-
cerol (PG) and phosphocholine (PC) vesicles using the calcein buffer instead
of the HEPES hydrolysis buffer during the lipid hydration step. Untrapped
calcein was removed from the liposome suspension by gel ﬁltration through a
column packed with Sephadex G-50 using the HEPES hydrolysis buffer as
an eluent. The vesicles are diluted 10-fold before being used in the activity
assay. After 100% release, the ﬂuorescence intensity of calcein as a function
of concentration is still within the linear response regime (34).
Measurement of PLA2 activity through indirect
calcein release from 1,2-di-O-SPC large
unilamellar vesicles
Measurement of the activity of PLA2 on different PG/PC mixtures at
different temperatures and phase states required an assay that would be
3166 Leidy et al.
Biophysical Journal 90(9) 3165–3175
insensitive both to temperature and to the phase behavior of the target
liposomes. For this reason we decided to measure PLA2 activity by
monitoring the release of calcein encapsulated in a self-quenching concen-
tration (50 mM) from 1,2-di-O-SPC large unilamellar vesicles (100 nm).
The 1,2-di-O-SPC vesicles are not hydrolyzed by PLA2, but, when added
together with the target PG/PC vesicles, the release of their calcein content is
triggered by the PG/PC hydrolysis products (34). The 1,2-di-O-SPC vesicles
have a high phase-transition temperature (Tm¼56C). Therefore, within our
experimental temperature range they are in a stable nonpermeable gel-phase
regime. We observed no calcein release from the 1,2-di-O-SPC vesicles
between 10 and 60C (data not shown). For every data point, 37 ml of the
PG/PC vesicles (10 mM) were added together with 25 ml of calcein
containing 1,2-di-O-SPC vesicles into 2.4 ml of HEPES hydrolysis buffer
within a cuvette. The cuvette was placed in a temperature-regulated cuvette
holder within the ﬂuorometer. Fluorescence measurements were performed
using an SLM DMX 1100 spectroﬂuorometer (SLM Instruments, Urbana,
IL). Excitation and emission channels were set at 490 nm and 515 nm,
respectively, and the emission ﬂuorescence was recorded as a function of
time. An initial baseline ﬂuorescence level was recorded in the ﬁrst 50 s.
PLA2 was added at this point, and calcein release was monitored. For each
experimental point, 10 ml of tear ﬂuid was used to monitor the human PLA2-
IIA activity, whereas 4.4 ml of snake venom PLA2 (42 mM) was used to
monitor the snake venom enzyme activity. Complete (100%) release was
obtained by adding 50 ml of 10% Triton X-100 either after a plateau release
level was obtained or after 1500 s in which no activity was observed.
Differential scanning calorimetry
Differential scanning calorimetry (DSC) was performed using a MicroCal
MC-2 (Northhampton, MA) on samples of 10 mM DMPC/DMPG multi-
lamellar vesicles at a scan rate of 10C/h. An appropriate baseline was
subtracted from the resulting thermograms. The onset and completion
temperatures used to compose the DMPC/DSPG phase diagram were
determined by intersecting the slope line at half-width on the peak heat
capacity and the baseline (35).
RESULTS AND DISCUSSION
Evaluating PLA2-IIA and snake venom PLA2
activity through an indirect calcein
release method
We were interested in evaluating the activity of PLA2 in a
time-dependent manner for a variety of temperatures, mem-
brane compositions, and phase states. For this reason we
needed a reporter system that was relatively insensitive to
both temperature and membrane phase behavior. An indirect
calcein release method was found to be the most appropriate
system (34). In this method, calcein-containing vesicles com-
posed of nonhydrolyzable 1,2-di-O-SPC ether lipids are
cosuspended with the PLA2 targeted vesicles. As the targeted
vesicles become hydrolyzed, the products of hydrolysis
diffuse into the nonhydrolyzable vesicles and trigger calcein
release (Fig. 1 a). The 1,2-di-O-SPC vesicles are stable in a
broad temperature regime. They have a gel/ﬂuid phase-
transition temperature (Tm ¼ 56C, as measured by DSC)
that is higher than the temperature range to be probed, and
they show no passive calcein release in the temperature range
between 10 and 55C (data not shown). As a result, the
calcein-containing vesicles are insensitive to changes in
temperature, are independent of the changes in composition
FIGURE 1 (a) Detection of PLA2-IIA activity through
release of calcein from nonhydrolyzable 1,2-di-O-SPC
vesicles containing self-quenching concentrations of the
ﬂuorophore. The release is induced by migration of prod-
ucts of hydrolysis from the PLA2-IIA targeted vesicles,
making the detection setup sensitive to PLA2-IIA activity,
but independent of membrane phase behavior of the target
system. (b) The activity of PLA2-IIA is assessed by
monitoring calcein release as a function of time. PLA2-IIA
is added at 50 s. Triton X-100 is added after the burst to
induce total calcein release. The maximum calcein release
rate (Rmax) is calculated by taking the maximum value in
the ﬁrst derivative of the activity trace. (c) Snake venom
PLA2 and human PLA2-IIA activity are assessed for
different experimental conditions speciﬁed at the column
axis. All columns have the reporter 1,2-di-O-SPC vesicles
present. The fourth column-set shows the activity of the
enzymes in the presence of a PLA2-IIA inhibitor (Ly). See
text for details.
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of the PLA2 targeted vesicles, and only become permeable
through the byproducts of the hydrolysis of the cosuspended
target vesicles.
Fig. 1 b shows a representative measurement of PLA2-IIA
activity on 1:1 DMPC/DMPG unilamellar vesicles at 25C.
The enzyme is added at 50 s, and after a lag period of;70 s,
a sharp increase in the intensity of the calcein ﬂuorescence
signal is observed, indicating the reaction burst. After the
PLA2 burst Triton X-100 is added to induce total release. As
a measure of enzyme activity, we calculated the maximum
calcein release rate (Rmax), deﬁned here as the inﬂection
point in the reaction time courses, by taking the maximum
value in the ﬁrst derivative of the data. In Fig. 1 c, we present
a series of control measurements at 25C, in which the
activities of PLA2-IIA and snake venom PLA2 are compared.
To check the reliability of our enzyme source and experi-
mental method we performed the following control measure-
ments to corroborate that 1), calcein release unrelated to the
PLA2 hydrolysis process is not observed after addition of
PLA2-IIA; 2), hydrolysis is indeed measurable for PLA2-IIA
for anionic lipid substrates; 3), PLA2-IIA shows speciﬁcity
toward anionic lipid membranes; and 4), no PLA2-IIA
activity is observed after treatment with a speciﬁc inhibitor.
Nonhydrolyzable 1,2-di-O-SPC vesicles are added in every
experimental condition in Fig. 1 c. The ﬁrst set of columns
(control) shows no enzyme activity for either the snake venom
or the human PLA2 species in the absence of target vesicles,
demonstrating that addition of either enzyme does not cause
nonspeciﬁc release from the 1,2-di-O-SPC vesicles. In the
next set of columns, both the snake venom PLA2 and human
PLA2-IIA show activity toward anionic 1:1 DMPC/DMPG
vesicles, with the snake venom PLA2 showing a higher
degree of activity compared to PLA2-IIA for the enzyme
concentrations used (see Materials and Methods). In the third
set of columns, we observe that in the presence of zwitterionic
DMPC vesicles only the snake venom enzyme is active,
corroborating the speciﬁcity of PLA2-IIA toward anionic
membranes. In the last set of columns, a speciﬁc PLA2-IIA
inhibitor is added. Total inhibition is observed for the human
PLA2-IIA. Partial inhibition is observed in the case of snake
venom PLA2, which is expected for the type of inhibitor
used.
Increased activity of PLA2-IIA in the ﬂuid-phase
regime for membranes enriched in anionic lipids
Extensive work has shown that snake venom PLA2 exhibits
increased activity in the presence of gel/ﬂuid domain coex-
istence (26–28). We were interested in determining whether
PLA2-IIA exhibits a similar sensitivity toward gel/ﬂuid
interfaces. To evaluate this in a model system, we chose a 1:1
DMPC/DMPG mixture (Fig. 2 a). Both lipids have the same
phase-transition temperature around 24C (as measured by
DSC) so the system is expected to behave as an ideal mix-
ture, exhibiting a narrow transition from gel to ﬂuid phase.
However, as in the case of pure DPPC, the 1:1 DMPC/
DMPG system is also expected to exhibit ﬂuid/gel domain
coexistence in the vicinity of 24C. Saturated PC/PG mix-
tures are well characterized thermodynamically so they con-
stitute a well deﬁned setting for a quantitative study. We do
not use 100% DMPG because the lipid is known to form
nonvesicular three-dimensional structures at the main phase
transition (36), which may restrict access to the enzyme.
Fig. 2 a shows the main phase transition of 1:1 DMPC/
DMPG vesicles at 24C as measured by differential scanning
calorimetry (a pretransition at 16C indicates ripple phase
formation). PLA2-IIA activity on 1:1 DMPC/DMPG vesicles
was measured using the indirect calcein release assay. The
lag time and the Rmax are also plotted as a function of tem-
perature in Fig. 2 a. In contrast to previous results on snake
venom PLA2 activity toward zwitterionic DPPC vesicles
(29), neither a maximum in the activity nor a minimum in the
lag time are observed at the main phase transition of the
system. Instead, there is an increase in the activity, as mea-
sured by the release rate, and a decrease in the lag time as the
FIGURE 2 (a) PLA2-IIA activity, and (b) snake venom PLA2 activity
toward 1:1 DMPG/DMPC small unilamellar vesicles are assessed by plot-
ting the maximum calcein release rate Rmax (d), and the lag time (s) as a
function of temperature. The thermotropic phase behavior as determined by
the heat capacity of 1:1 DMPG/DMPC multilamellar vesicles is also plotted
in a and b to denote the gel/ﬂuid phase transition of the system.
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system enters the ﬂuid-phase temperature regime. This im-
plies that, at least for the anionic/zwitterionic mixed system,
PLA2-IIA does not rely on gel/ﬂuid heterogeneities to access
the substrate. The enzyme is therefore able to hydrolyze the
negatively charged membrane in the ﬂuid-phase regime.
The ability of PLA2-IIA to hydrolyze the ﬂuid phase of
the 1:1 DMPC/DMPG system in the absence of a gel/ﬂuid
domain structure could be a speciﬁc characteristic of PLA2-IIA
that distinguishes the enzyme from the snake venom species.
To test this, we evaluated the activity of snake venom PLA2
on the anionic/zwitterionic 1:1 DMPC/DMPG system. Fig. 2
b shows that snake venom PLA2 also exhibits increased
activity in the ﬂuid-phase regime of the 1:1 DMPC/DMPG
system relative to the gel phase, also in contrast to what was
found for the activity of snake venom PLA2 on DPPC
bilayers (29). The increased activity of PLA2-IIA in the ﬂuid-
phase regime is therefore not an intrinsic property of the
enzyme, but is a result of the properties of the anionic
enriched substrate, which provides access to the enzyme in
the ﬂuid-phase regime. We rule out that the shorter chain
length of the DMPC/DMPG system compared to the DPPC
system induces this difference in behavior, since the same
result as in Fig. 2 is obtained for the DPPC/DPPG system
(data not shown). The increased activity of PLA2-IIA in the
ﬂuid-phase regime is then likely to be due either to the pres-
ence of the charged lipid that increases access to the sub-
strate, or to heterogeneities in the ﬂuid phase due to the
presence of two distinct headgroups. In either case, the result
does inﬂuence our understanding of the activation of PLA2-
IIA in the presence of anionic lipids, since the enzyme does
not necessitate the presence of a ﬂuid/gel interface for acti-
vation. In addition, the model system we use to evaluate
PLA2-IIA activity probably more closely resembles the situ-
ation in a cell membrane, where one would expect hetero-
geneous lipid composition to be present in the ﬂuid phase.
The result does not contradict earlier ﬁndings with snake
venom PLA2 on zwitterionic systems, where the enzyme is
indeed activated by ﬂuid/gel domain formation. It is the pres-
ence of the anionic DMPG species that induces the increased
activity in the ﬂuid phase observed in Fig. 2.
Fig. 3 shows that the activity of PLA2-IIA continues to
increase with temperature up to 52C, where a sudden drop
in activity is observed. This sudden drop in enzyme activity
above 52C is reproducible in other systems, including the
1:1 DPPC/DPPG vesicles (data not shown). We therefore
attribute this to thermal denaturation of the human PLA2-IIA
enzyme. The enzyme behavior between 27 and 50C is
attributed to a thermally induced increase in enzyme activity.
A plot of the logarithm of the calcein release rate versus the
inverse in temperature appears linear between 30 and 50C
(data not shown), suggesting thermal activation of the
enzyme. However, it should be noted that the ﬂuorescence
assay is not a direct measure of enzyme activity; therefore,
this result is only suggestive and not strictly quantitative of a
thermal increase in enzyme activity between 30 and 50C.
From Figs. 2 and 3 it is clear that PLA2-IIA shows increased
activity throughout the ﬂuid-phase regime in membranes
enriched in anionic DMPG.
Fig. 4 shows a plot of the activity of PLA2-IIA as a
function of DMPG percentage in DMPC/DMPG vesicles in
the ﬂuid-phase regime at 30C. The plot shows the sigmoidal
increase in activity with anionic lipid content expected for
the interaction between the positively charged PLA2-IIA
interface and the anionic membrane surface. The DMPG
threshold concentration necessary for activation of PLA2-IIA
is then measured to be;38 mol % DMPG. This threshold is
higher than that reported for model systems using phospha-
tidylserine as the anionic species (14), which could be due to
differences in the exposure of the hydrolysis site between the
two headgroups. However, this needs to be investigated
further.
FIGURE 3 Detecting the denaturation temperature for PLA2-IIA by
monitoring the loss of enzyme activity for 1:1 DMPG/DMPC unilamellar
vesicles as a function of temperature. PLA2-IIA activity is assessed by plot-
ting maximum calcein release rates (Rmax) as a function of temperature.
FIGURE 4 PLA2-IIA activity as a function of composition assessed by
plotting maximum calcein release rates (Rmax) as a function of DMPGmol %
in DMPG/DMPC mixtures at 30C.
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Activation of PLA2-IIA in the presence of
ﬂuid-phase lipid domains enriched in
anionic lipids
In Fig. 2, it was shown that the presence of a ﬂuid/gel domain
interface does not enhance the activity of PLA2-IIA, at least
in comparison to the activity of the enzyme toward ﬂuid-
phase membranes enriched in anionic lipids. This result ap-
pears to indicate that the structural heterogeneity that arose
from gel/ﬂuid domain formation may not enhance the activ-
ity of PLA2-IIA. However, we propose that domain forma-
tion can play a role in enhancing PLA2-IIA activity in the
regime with lower anionic content by providing composi-
tional heterogeneity. Based on the results from Fig. 2, which
show that PLA2-IIA exhibits high activity toward anionic
ﬂuid-phase membranes, we focus on how the formation of
ﬂuid-phase domains may trigger the activation of PLA2-IIA
through local enrichment with anionic lipids induced by lipid
phase separation.
To investigate this proposal we chose a simple 30:70
DMPG/DSPC system, which presents a broad ﬂuid/gel coex-
istence regime characterized by DMPG-enriched anionic ﬂuid-
phase domains and DSPC-enriched zwitterionic gel phase
domains. Although the domain size should be dependent on
the equilibration time, the composition of the domains is
clearly deﬁned by the phase boundaries. The overall DMPG
content of this system is lower than the DMPG threshold
concentration of 38 mol % presented in Fig. 4, so no activity
is expected when the anionic lipid is evenly dispersed in
the membrane. Fig. 5 b presents a DSC scan of 30:70
DMPG/DSPC multilamellar vesicles. The broad heat capac-
ity proﬁle between 35C and 46C indicates the main
melting event of the system and demarcates the region of
ﬂuid/gel phase-domain coexistence. The lower temperature
event at 22C is the pretransition indicating the formation of
the ripple phase. The domain structure within the main melt-
ing region (between 35C and 46C) is characterized by the
presence of ﬂuid-phase domains enriched in the lower melt-
ing component (negatively charged DMPG in this case), and
gel-phase domains enriched in the higher melting component
(zwitterionic DSPC) (37). We have indicated three different
temperature points in the DSC trace (Fig. 5 b, I–III), which
we evaluate with respect to PLA2-IIA activity. Region I is
below the main melting event and is characterized by the
membrane being fully in gel phase. Region II is character-
ized by the presence of ﬂuid-phase domains enriched in
DMPG (therefore highly anionic) and gel-phase domains
enriched in DSPC. Region III is above the main melting
event and is characterized by the membrane being fully in the
ﬂuid phase, and by having the anionic lipids evenly dis-
persed in the membrane. The three situations are represented
by a cartoon in Fig. 5 a.
A 30:70 DMPC/DSPG system (IV) is also evaluated for
PLA2-IIA activity, where the headgroups of the lower-melting-
temperature component and the higher-melting-temperature
component have been switched. This system has a gel/ﬂuid
coexistence temperature range similar to that of DMPG/
DSPC, except that it is characterized by the presence of ﬂuid-
phase domains enriched in zwitterionic DMPC and gel-phase
domains enriched in anionic DSPG. We expect low PLA2-
IIA activity in this case, since the ﬂuid-phase domains are
enriched in a zwitterionic lipid (Fig. 5 a-IV).
In Fig. 5 c, the level of activity of PLA2-IIA toward the
four systems is evaluated. PLA2-IIA shows no activity when
the 30:70 DMPG/DSPC vesicles are in the gel-phase regime
(I). It should be pointed out that not even a baseline level of
activity is observed, in contrast to a small but signiﬁcant
level of activity previously observed (Fig. 2 a) in the gel
phase for 1:1 DMPG/DMPC vesicles. This indicates that in
addition to the reduced activity of PLA2-IIA toward the gel
phase, the low DMPG level leads to a further reduction in
activity. PLA2-IIA also shows low activity in the ﬂuid-phase
regime (III), where the DMPG lipids are expected to be
evenly distributed in the membrane and the local concentra-
tion of DMPG is lower than the anionic lipid threshold. In
contrast, PLA2-IIA shows signiﬁcant activity in the presence
of ﬂuid/gel domain coexistence (II), where the ﬂuid-phase
domains are enriched in DMPG. This result shows that local
enrichment in anionic lipids can overcome the anionic lipid
threshold needed to trigger PLA2-IIA activity. No activity is
observed in region IV, where the ﬂuid-phase domains are
enriched in a zwitterionic lipid (DMPC) and the gel-phase
domains are enriched in the anionic lipid (DSPG), showing
that it is speciﬁcally the ﬂuid-phase domains enriched in
anionic lipids that can trigger PLA2-IIA activity. As controls
we tested the activity of snake venom PLA2 on the 30:70
DMPC/DSPG system (Fig. 5 c, ﬁfth column). As expected,
the snake venom enzyme shows activity in the presence of
zwitterionic ﬂuid-phase domains, in contrast to PLA2-IIA,
which shows no activity toward the 30:70 DMPC/DSPG
system (Fig. 5 c, fourth column). PLA2-IIA activity in 1:1
DMPG/DMPC at 50C (Fig. 5 c, sixth column) has also been
tested to make sure that the lack of activity in region III is not
due to enzyme denaturation.
The DMPG/DSPC phase diagram predicts the
windows of activity for PLA2-IIA
In Fig. 6, we compare the activity window of PLA2-IIA to
the thermotropic behavior, as measured by DSC, for three
different DMPG/DSPC compositions. Fig. 6 a shows the
activity window of a 1:1 DMPG/DSPC system, which ranges
from 22C to 52C. The gel-ﬂuid coexistence regime, as
determined by the 1:1 DMPG/DSPC thermogram, ranges
from 28C to 42C. The DMPG content of this system is
higher than the anionic lipid threshold concentration for
activation; therefore, PLA2-IIA should show activity in the
ﬂuid-phase regime when DMPG is evenly distributed. As
expected, PLA2-IIA activity continues increasing in an
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Arrhenius manner in the ﬂuid-phase regime until the
denaturation temperature of the enzyme at 52C. In the
lower temperature range the window of activity for PLA2-
IIA extends unexpectedly below the gel/ﬂuid coexistence
regime. An explanation for this may be the presence of the
ripple phase between 20C and 28C. Previously, we
showed that the ripple phase enhances the activity of snake
venom PLA2 in DMPC/DSPC mixtures compared to the gel
phase (38,39). The increased local curvature due to the
ripples may not in itself necessarily lead to an increase in
PLA2-IIA activity, considering that we found that the gel/
ﬂuid interface does not enhance PLA2-IIA activity (Fig. 2 a).
However, in addition it was found that snake venom PLA2
showed preferential hydrolysis of the lower melting compo-
nent in the DMPC/DSPC system, which appeared to indicate
a degree of phase separation in the ripple-phase regime
(38,39). The increased activity of PLA2-IIA in the ripple-
phase regime may also be related to a certain degree of phase
separation between DMPG and DSPC.
Fig. 6 b presents the PLA2-IIA activity window for a
30:70 DMPG/DSPC system. It can be seen that the enzyme
activity is restricted to the ﬂuid/gel coexistence regime,
where the ﬂuid-phase domains are enriched in DMPG. In
contrast to Fig. 6 a, no activity is observed in the ﬂuid-phase
regime for the 30:70 DMPG/DSPC system. In Fig. 6 c, we
evaluate the activity window for the 20:80 DMPG/DSPC
system. The activity of the enzyme is also restricted to the
gel/ﬂuid coexistence regime, and no activity is observed in
the ﬂuid-phase regime. The maximum activity in the 20:80
DMPG/DSPC system is signiﬁcantly lower than in the 30:70
DMPG/DSPC system. This point is addressed later in the
discussion of Fig. 7 b.
Fig. 7 a shows the DMPG/DSPC phase diagram as deter-
mined by DSC. The gel/ﬂuid coexistence regime is deﬁned
FIGURE 5 (a) Cartoon of unilamellar vesicles present-
ing the following phase states and membrane domain struc-
tures: (I) all gel phase at 30C; (II) coexisting ﬂuid and gel
phase domains at 40C, where the ﬂuid-phase domains are
enriched in the anionic lipid DMPG; (III) all ﬂuid phase at
50C; and (IV) coexisting ﬂuid and gel phase domains
where the ﬂuid-phase domains are enriched in the zwitter-
ionic lipid DMPC. Regions I–III are from vesicles of the
same composition, 30:70 DMPG/DSPC; in region IV, the
composition is 30:70 DMPC/DSPG unilamellar vesicles.
(b) Thermotropic phase behavior (heat capacity) of the
30:70 DMPG/DSPC samples showing the three phase-
behavior scenarios (for regions I–III) as different points in
the thermogram. (c) PLA2-IIA activity toward the four
systems presented in a. The activity of snake venom PLA2
is assessed for region IV in the ﬁfth column, and the
activity of PLA2-IIA is assessed at 50C for 1:1 DMPG/
DSPC vesicles in the sixth column.
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by the solidus and ﬂuidus phase lines (solid lines with solid
circles), which are determined from the onset and comple-
tion temperatures of the main melting event in the DSC
thermograms. The solidus (bottom) phase line corresponds to
a cooperative transition from 100% gel phase to gel/ﬂuid
coexistence, whereas the ﬂuidus (top) phase line corresponds
to a cooperative transition from 100% ﬂuid phase to gel/ﬂuid
coexistence. The additional lines that are drawn into the phase
diagram are related to the enzyme activity. The top hori-
zontal dashed line crossing at 52C corresponds to the
denaturation temperature of the enzyme, and the vertical
dashed line crossing at 64 mol % DSPC corresponds to the
DMPG threshold concentration for PLA2-IIA activation. In
the absence of a ﬂuid/gel domain structure, the rectangular
region demarcated by these two dashed lines (T , 52C;
% DSPC , 64) would deﬁne the activity window of the
enzyme.
However, due to the presence of ﬂuid/gel domains orig-
inating in the phase diagram, an additional region of activity
stretches into the low-DMPG-concentration regime (right-
hand side of the phase diagram). This region of activity is
expected to be delimited by the solidus phase line (where the
anionic ﬂuid-phase domains nucleate), and a higher temper-
ature border determined by a tie-line in the phase diagram
(second horizontal dashed line crossing at ;46C). This tie
line corresponds to ﬂuid-phase domains with DMPG content
equal to the anionic lipid threshold. Above this tie line, the
ﬂuid-phase domains will have a DMPG content lower than
the anionic lipid threshold.
The shaded area therefore corresponds to the region in
the phase diagram where ﬂuid-phase formation is expected,
and where the ﬂuid phase will have a DMPG concentration
greater than the anionic lipid threshold for PLA2-IIA acti-
vation. The shaded area is also limited by the denaturation
temperature of the enzyme. It therefore corresponds to the
region in the phase diagram where PLA2-IIA activity is
expected.
We have included the experimental data as three verti-
cal bars in Fig. 7 a corresponding to the activity windows
observed for the 50:50, 30:70, and 20:80 DMPG/DSPC
vesicles as measured in Fig. 6. The length of the vertical bars
was determined from Fig. 6, a–c, by taking the temperatures
corresponding to an activity value of at least 20% of the
maximum activity observed for the corresponding compo-
sition. We observe that the bars correspond closely to the
shaded area in the higher-temperature border (Fig. 7 a). In
the case of the 50:50 DMPG/DSPC sample the activity win-
dow extends by several C into the ripple phase regime. As
discussed previously, the activity in the ripple-phase regime
may be explained by phase separation of a small fraction
of the lower melting temperature component in the ripple
structure (38,39); however, this needs further investigation to
be corroborated. The bars corresponding to the lower anionic
lipid concentrations at 30:70 and 20:80 ﬁt more closely to the
boundaries of the activity window.
An additional result that may be explained by the DMPG/
DSPC phase diagram is the reduction in maximum activity
observed in the 20:80 sample compared to the 30:70 sample.
Fig. 7 b shows the two vertical activity windows corre-
sponding to the two compositions. Tie lines have been drawn
through the midpoint of each activity window. With the use
of the lever rule, the fractions of ﬂuid phase and gel phase
corresponding to each composition at the midpoint of the
activity window can be determined. It is clear that the per-
centage of ﬂuid phase available for hydrolysis in the 20:80
sample is much smaller than in the 30:70 sample, which
explains the ﬁvefold reduction in activity observed in Fig. 6.
This reduction in activity is explained by a reduction of the
ﬂuid-phase fraction available for hydrolysis.
FIGURE 6 PLA2-IIA activity as a function of temperature for (a) 1:1
DMPG/DSPC, (b) 30:70 DMPG/DSPC, and (c) 20:80 DMPG/DSPC
unilamellar vesicles. The thermotropic phase behavior as measured by
DSC of each one of the systems is included to indicate the ﬂuid/gel
coexistence regimes.
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CONCLUSION
In this work, we have shown that local enhancement of
anionic lipid concentrations induced by domain formation
can trigger PLA2-IIA activity. The formation of ﬂuid-phase
domains enriched in anionic lipids may explain, at least in
part, the activation of PLA2-IIA toward perturbed cell mem-
brane systems that have undergone loss in membrane asym-
metry. The low global levels of anionic lipids in cell plasma
membranes appear to be less than the anionic lipid content
required for activation (14). However, the activity of PLA2-
IIA during inﬂammatory response indicates that the enzyme
is able to hydrolyze perturbed host cell systems (9,25).
Plasma membranes have been shown to form lipid domain
systems (40–42) through phase separation of liquid-ordered
phase domains or lipid rafts, which are enriched in both cho-
lesterol and high-melting-temperature components such as
sphingomyelin (20). The formation of these cholesterol-
enriched domains entails the presence of coexisting cholesterol-
poor ﬂuid-phase domains enriched in low-melting-temperature
components. Anionic lipids in the cell plasmamembrane, such
as phosphatidylserine, are characterized by having unsatu-
rated chains (43), and would therefore tend to prefer the ﬂuid-
phase domains. One of the targets of PLA2-IIA hydrolysis that
plays an important role during the inﬂammatory response is
arachadonic acid (25); a highly unsaturated fatty acid likely
to induce its corresponding phospholipid to partition into the
ﬂuid-phase domains. The activation of PLA2-IIA toward per-
turbed cellular systems may be induced by the formation of
lipid domains enriched in unsaturated anionic lipids.
To understand in more depth the behavior of PLA2-IIA in
the presence of coexisting phases, it was necessary to embark
on a fundamental study with a simple two-component do-
main system. This study opens the door for the analysis of
PLA2-IIA activity in more complex mixtures that include
cholesterol and reﬂect the composition of eukaryotic cell
membranes. Although extensive work has shown that snake
venom PLA2 presents an increase in activity in the presence
of domain interface defects, no biophysical studies have been
performed on the effects of lipid domain structures on the
human enzyme. It is clear from this study that in the presence
of membranes containing anionic lipids, human PLA2-IIA is
strongly regulated by membrane composition and not by
the presence of domain interface defects. This observation
changes the perception of the factors that regulate PLA2-IIA
activity in cell membranes, and it lays the groundwork for
studying the activity of human PLA2-IIA in the presence of
more complex domain systems.
This study has also shown that PLA2-IIA activity could be
mapped onto a multi-component phase diagram where the
domain fractions and compositions are well deﬁned, and
where the anionic lipid content of the ﬂuid-phase domains can
be determined based on the phase lines. In this way, the
anionic lipid content in the ﬂuid-phase domains can be clearly
related to the anionic lipid threshold of the enzyme. The same
strategy can be followed to evaluate the activity of the enzyme
within more complex phase diagrams that might lead to a more
detailed understanding of the phase behavior and domain
structures found in perturbed cell membranes and their role
in regulating activity. Three-component phase diagrams
(1-palmitoyl, 2-oleoyl phosphatidylcholine-sphingomyelin-
cholesterol), which reﬂect the phase behavior of cell mem-
branes more closely, are becoming available (44–46). It would
be necessary to include phosphatidylserine in the development
of more complex phase diagrams to begin testing some
predictions of the compositional regions where activation of
human PLA2-IIA may be expected. It is likely that cholesterol
will play a key role in regulating the nature of the domains
present, and the possibility for activation of PLA2-IIA.
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